Business News • PR NewsWire • Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010

Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010

Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010

PHILADELPHIA, Sept. 25 /PRNewswire/ -- Today Astellas Pharma US, Inc. ("Astellas") announced results of a Phase IV study showing Lexiscan® (regadenoson) Injection was comparable to placebo in causing a >15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or

View More : http://www.prnewswire.com/news-releases/lexiscan-regadenoson-injection-study-in-subjects-with-asthma-or-chronic-obstruct...

Releted News by prnewswire

Freelancer.com Catapults Past 1,800,000 Users and 800,000 Completed Jobs on International Freelancer Day as the World's Leading Outsourcing Marketplace

CBC RADIO WINS BIG AT "WORLD'S BEST RADIO PROGRAMS" AWARDS IN NEW YORK

Planes, Trains and 'BlogMobiles': One Nation Working Together Supporters Embark on Nationwide Journey

Predicting Clinical Outcomes With Noninvasive Cardiac Imaging: One-Year Follow Up Results From the SPARC Study